Advertisement
Singapore markets close in 3 hours 50 minutes
  • Straits Times Index

    3,160.24
    +15.48 (+0.49%)
     
  • Nikkei

    38,293.03
    -178.17 (-0.46%)
     
  • Hang Seng

    16,238.09
    -10.88 (-0.07%)
     
  • FTSE 100

    7,820.36
    -145.17 (-1.82%)
     
  • Bitcoin USD

    64,253.66
    +1,692.49 (+2.71%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     
  • Dow

    37,798.97
    +63.86 (+0.17%)
     
  • Nasdaq

    15,865.25
    -19.77 (-0.12%)
     
  • Gold

    2,397.80
    -10.00 (-0.42%)
     
  • Crude Oil

    84.91
    -0.45 (-0.53%)
     
  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     
  • FTSE Bursa Malaysia

    1,533.76
    -1.24 (-0.08%)
     
  • Jakarta Composite Index

    7,168.71
    +3.91 (+0.05%)
     
  • PSE Index

    6,466.67
    +61.70 (+0.96%)
     

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc.

STAMFORD, Conn., Feb. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will present at the following investor conferences:

  • TD Cowen 44th Annual Health Care Conference on Monday, March 4 at 2:50 p.m. E.T.

  • Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12 at 9:00 a.m. E.T.

Webcasts of these events will be available on the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. Replays of the webcasts will be available on SpringWorks’ website for a limited time following each conference.

ADVERTISEMENT

About SpringWorks Therapeutics

SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer.

Founded in 2017, SpringWorks has a diversified targeted oncology pipeline spanning solid tumors and hematological cancers, including clinical trials in rare tumor types and highly prevalent, genetically defined cancers. OGSIVEO™, approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is SpringWorks’ first FDA-approved therapy. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its lead product candidates into late-stage trials and enter into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer.

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.

Contacts:
Kim Diamond
Vice President, Communications and Investor Relations 
Phone: 203-561-1646
Email: kdiamond@springworkstx.com

Samantha Hilson Sandler 
Senior Director, Investor Relations 
Phone: 203-461-5501 
Email: samantha.sandler@springworkstx.com